Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 2, 1997, Pages 810-816

  Henry, Scott P ^a   Giclas, Patricia C ^b   Leeds, Janet ^a   Pangburn, Michael ^c   Auletta, Carol ^d   Levin, Arthur A ^a   Kornbrust, Douglas J ^e  

^a ISIS PHARMACEUTICALS   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF TEXAS AT TYLER   (United States)

^d Huntingdon Life Sciences New Jersey   (United States)

^e CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; PRIORITY JOURNAL;

ANIMALS; COMPLEMENT PATHWAY, ALTERNATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA FASCICULARIS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; ORGANOPHOSPHORUS COMPOUNDS; THIONUCLEOTIDES;

EID: 0030922755     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. BITTER-SUERMANN, D., BURGER, R. AND HADDING, U.: Activation of the alternative pathway of complement: Efficient fluid-phase amplification by blockade of the regulatory complement protein B1H through sulfated polyanions. Eur. J. Immunol. 11: 291-295, 1981.
2. BOACKLE, R. J., CAUGHMAN, G. B., VESELY, J., MEDGYESI, G. AND FUDENBERG, H.: Potentiation of factor H by heparin: A rate-limiting mechanism for inhibition of the alternative complement pathway. Mol. Immunol. 20: 1157-1164,1983.
3. CORNISH, K.G., IVERSEN, P., SMITH, L., ARNESON, M. AND BAYEVER, E.: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious cynomolgus monkey. Pharmacol. Res. Commun. 3: 239-247, 1993.
4. CROOKE, S. T.: Therapeutic application of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32: 329-376, 1992.
5. CROOKE, S. T.: Progress in antisense therapeutics. Hematol. Pathol. 9: 59-72, 1995.
6. EHRENGRUBER, M. U., GEISER, T. AND HERANLEAU, D. A.: Activation of human neutrophils by C3a and C5a comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. Fed. Eur. Biochem. Soc. 346: 181-184, 1994.
7. EMBER, J. A., SANDERSON, S. D., TAYLOR, S. M., KAWAHARA, M. AND HUGLI, T. E.: Biologic activity of synthetic analogues of C5a anaphylatoxin. J. Immunol. 148: 3165-3173, 1992.
8. FRANK, M. M. AND FRIES, L. F.: The role of complement in inflammation and phagocytosis. Immunol. Today 12: 322-326, 1991.
9. GALBRAITH, W. M., HOBSON, W. C., GICLAS, P. C., SCHECHTER, P. J. AND AGRAWAL, S.: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206, 1994.
10. GARDNER, W. D., HASELBY, J. A. AND HOCH, S. O.: Identification of a major serum DNA-binding protein as Factor B of the alternative complement pathway J. Immunol. 124: 2800, 1980a.
11. GARDNER, W. D., WHITE, P. J. AND HOCH, S. O.: IDENTIFICATION OF A MAJOR HUMAN SERUM DNA-PROTEIN AS B1H OF THE ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION. BIOCHEM. BIOPHYS. RES. COMMUN. 94: 61-67, 1980B.
12. HARBECK, R. J. AND GICLAS, P. C.: Complement levels by radialimmunodiffusion. In Diagnostic Immunology Laboratory Manual, pp. 9-20, Raven Press, New York, 1991.
13. HENRY, S. P., BOLTE, H., AULETTA, C. AND KORNBRUST, D.: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology, in press, 1996a.
14. HENRY, S. P., ORR, J. L., BRUNNER, R. H. AND KORNBRUST, D. J.: Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology 116: 77-88, 1997.
15. HENRY, S. P., TAYLOR, J., MIDGLEY, L., LEVIN, A. A. AND KORNBRUST, D. L.: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleotide Drug Dev. in press, 1996b.
16. HUGLI, T. E. AND MULLER-EBERHARD, H. J.: Anaphylatoxins: C3a and C5a. Adv. Immunol. 26: 1-53, 1978.
17. KAJITA, T. AND HUGLI, T. E.: C5a-induced neutrophilia: A primary humoral mechanism for recruitment of neutrophils. Am. J. Pathol. 137: 467-477, 1990.
18. LEEDS, J. M., GRAHAM, M. J., TRUONG, L. AND COMMINS, L. L.: Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235: 36-43, 1996.
19. MERI, S. AND PANGBURN, M. K.: Discrimination between activators and nonactivators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. U.S.A. 87: 3982-3986, 1990.
20. PANGBURN, M. P., ATKINSON, M. A. L. AND MERI, S.: Localization of the heparin binding site on complement factor H. J. Biol. Chem. 266:16847-16853, 1991.
21. PANGBURN, M. K. AND MULLER-EBERHARD, H. J.: The alternative pathway of complement. Springer Semin. Immunopathol. 7: 163-192, 1984.
22. SARMIENTO, U. M., PEREZ, J. R., BECKER, J. M. AND NARAYANAN, R.: In vivo toxicological effects of rel A antisense phosphorothiote in CD-1 mice. Antisense Res. Dev. 4: 99-107, 1994.
23. SCHREIBER, R. D., PANGBURN, M. K., LESAVRE, P. H. AND MULLER-EBERHARD, H. J.: Initiation of the alternative pathway of complement: Recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. U.S.A. 75: 3948-3952, 1978.
24. SRINIVASAN, S. K. AND IVERSEN, P.: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9: 129-137, 1995.
25. SVEHAG, S.-E.: Adverse effects of clinical intervention on the complement system. Comp. Inflam. 8: 359-369, 1991.
26. TOMLINSON, S.: Complement defense mechanisms. Curr. Biol. Lim. 5: 83-89, 1993.
27. WAGNER, R. W.: Gene inhibition using a antisense oligodeoxynucleotides. Nature (Lond.) 372: 333-335, 1994.